Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06173531 · ClinicalTrials.gov registry record · Phase 3
Study of Carbetocin Nasal Spray for the Treatment of Hyperphagia in Prader-Willi Syndrome
A Phase 3 study of Hyperphagia in Prader-Willi Syndrome, sponsored by ACADIA Pharmaceuticals.
- Active
- Registry status
- Phase 3
- Development phase
- 170
- Enrollment target
- 20
- Study locations
NCT06173531: Active Phase 3 study of Hyperphagia in Prader-Willi Syndrome, sponsored by ACADIA Pharmaceuticals.
NCT06173531 is a Phase 3 study of Hyperphagia in Prader-Willi Syndrome that is active but no longer recruiting, run by ACADIA Pharmaceuticals. The registered enrollment target is 170 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (78% lower). The trial reports 20 study locations across 16 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06173531, a Phase 3 study of Hyperphagia in Prader-Willi Syndrome, is active but no longer recruiting, sponsored by ACADIA Pharmaceuticals.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 170 participants
- Enrollment target
- 20
- Study locations
Study Summary
12-week, randomized, double-blind, placebo-controlled, parallel-group study of carbetocin nasal spray for the treatment of hyperphagia in Prader-Willi syndrome (PWS)
Primary Outcome
The HQ-CT is a nine-item questionnaire designed to be completed by caregivers of subjects with PWS. It is a revision of the 11-item HPWSQ-R and has been further validated. The Foundation for Prader-Willi Research has made the HQ-CT available for clinical studies in PWS, and it is the consensus instrument within the PWS research community for measuring observable behaviors that stem from subjects' excessive drive to eat. The HQ-CT should be completed by the same caregiver throughout the study. T
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Carbetocin
Study Locations (20)
California
- University of California Irvine - Orange
- Stanford University School of Medicine - Palo Alto
- Rady Children's Hospital San Diego - San Diego
Missouri
- Children's Mercy Hospital - Kansas City
- SSM Health/Saint Louis University - St Louis
Texas
- Cook Children's Health Care System - Fort Worth
- Christus Children's - San Antonio
Alabama
- Children's of Alabama - Birmingham
Arizona
- Phoenix Children's Hospital - Phoenix
Colorado
- Children's Hospital Colorado - Aurora
Illinois
- Ann & Robert H. Lurie Children's Hospital of Chicago - Chicago
Iowa
- University of Iowa - Iowa City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 170 participants |
| Start Date | 2023-11-27 |
| Est. Completion | 2025-11 |
| Phase | Phase 3 |
What the registry record for NCT06173531 still lists
NCT06173531 is an interventional study that assigns participants to a tested intervention. The registered 170 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (78% lower).
The record links to 1 condition, with Hyperphagia in Prader-Willi Syndrome appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06173531 names 20 study sites across 16 states, led by California, Missouri, Texas.
Frequently Asked Questions
What is clinical trial NCT06173531 about?
NCT06173531 is a clinical study titled "Study of Carbetocin Nasal Spray for the Treatment of Hyperphagia in Prader-Willi Syndrome". 12-week, randomized, double-blind, placebo-controlled, parallel-group study of carbetocin nasal spray for the treatment of hyperphagia in Prader-Willi syndrome (PWS)
What is the current status of trial NCT06173531?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 170 participants. The study started on 2023-11-27. Estimated completion is 2025-11.
What conditions does trial NCT06173531 study?
This clinical trial studies the following conditions: Hyperphagia in Prader-Willi Syndrome.
What interventions are being tested in trial NCT06173531?
The interventions under investigation include: Placebo (DRUG), Carbetocin (DRUG).
Who is sponsoring clinical trial NCT06173531?
This trial is sponsored by ACADIA Pharmaceuticals, which has 35 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06173531 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06173531's enrollment target sits among peer trials
170 1453rd of 2000 higher than 542 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02016430 · 170 participants · NA
Gut Flora Metabolite Reduction After Dietary Intervention (GRADY)
- NCT02621021 · 170 participants · Phase 2
A Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab
- NCT04094701 · 170 participants · NA
Hip Arthroscopy Postoperative Opioid Demands
- NCT04166409 · 170 participants · Phase 3
A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With Low-Grade Glioma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI